SOPHiA GENETICS announced an expanded collaboration with AstraZeneca to accelerate the global deployment of MSK-ACCESS® powered with SOPHiA DDM™. Building on an initial collaboration announced in October 2024, this new phase will extend the liquid biopsy test's reach to a total of 30 clinical institutions worldwide in 2025.
MSK-ACCESS®, developed in collaboration with Memorial Sloan Kettering Cancer Center, is an innovative liquid biopsy testing application designed to detect actionable genomic alterations from a single blood draw. It utilizes proprietary, state-of-the-art algorithms to analyze circulating tumor DNA (ctDNA), supporting real-time cancer monitoring and treatment selection.
The expanded rollout will contribute to AstraZeneca's global real-world evidence initiatives and further validate the clinical impact of decentralized liquid biopsy testing across diverse healthcare systems. SOPHiA GENETICS also presented data at AACR demonstrating the robust transferability and consistent accuracy of MSK-ACCESS® across various laboratory settings, aligning with the original single-site test performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.